Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novelos Therapeutics has received new patent from the US Patent and Trademark Office extending the composition and method of use claims relating to Nov-002, the company's lead compound in an ongoing pivotal Phase III trial for non-small cell lung cancer under a special protocol assessment and fast track.
Subscribe to our email newsletter
Novelos’s NOV-002 has demonstrated positive results in Phase II trials for other oncology indications.
Overall, Novelos filed more than 30 patent applications worldwide. Together, these will provide broad and long-lasting coverage, up to at least 2019, encompassing composition of matter, method of use and manufacturing for Novelos’s compounds.
Christopher Pazoles, vice president of R&D at Novelos, said: “This most recent addition to our IP portfolio further strengthens Novelos’s proprietary position in the oxidized glutathione field in general and, in particular, around the structure of Nov-002.”